- Home
- ANAB vs AVNS Comparison
ANAB vs AVNS Comparison
Compare ANAB & AVNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANAB
- AVNS
- Stock Information
- Founded
- ANAB 2005
- AVNS 2014
- Country
- ANAB United States
- AVNS United States
- Employees
- ANAB N/A
- AVNS N/A
- Industry
- ANAB Biotechnology: Pharmaceutical Preparations
- AVNS Industrial Specialties
- Sector
- ANAB Health Care
- AVNS Health Care
- Exchange
- ANAB Nasdaq
- AVNS Nasdaq
- Market Cap
- ANAB 759.5M
- AVNS 641.7M
- IPO Year
- ANAB 2017
- AVNS N/A
- Fundamental
- Price
- ANAB $19.59
- AVNS $12.64
- Analyst Decision
- ANAB Buy
- AVNS Hold
- Analyst Count
- ANAB 10
- AVNS 1
- Target Price
- ANAB $37.75
- AVNS N/A
- AVG Volume (30 Days)
- ANAB 589.1K
- AVNS 504.3K
- Earning Date
- ANAB 05-05-2025
- AVNS 05-06-2025
- Dividend Yield
- ANAB N/A
- AVNS N/A
- EPS Growth
- ANAB N/A
- AVNS N/A
- EPS
- ANAB N/A
- AVNS N/A
- Revenue
- ANAB $111,872,000.00
- AVNS $689,200,000.00
- Revenue This Year
- ANAB N/A
- AVNS N/A
- Revenue Next Year
- ANAB $44.69
- AVNS $3.36
- P/E Ratio
- ANAB N/A
- AVNS N/A
- Revenue Growth
- ANAB 387.20
- AVNS 1.34
- 52 Week Low
- ANAB $12.21
- AVNS $11.84
- 52 Week High
- ANAB $41.31
- AVNS $25.36
- Technical
- Relative Strength Index (RSI)
- ANAB 48.98
- AVNS 46.27
- Support Level
- ANAB $18.51
- AVNS $12.35
- Resistance Level
- ANAB $21.52
- AVNS $13.31
- Average True Range (ATR)
- ANAB 1.16
- AVNS 0.44
- MACD
- ANAB -0.26
- AVNS 0.12
- Stochastic Oscillator
- ANAB 26.97
- AVNS 50.92
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About AVNS Avanos Medical Inc.
Avanos Medical Inc is a United States-based company that develops and sells medical devices and related services globally. Its operating and reportable segment provides medical device products to healthcare providers and patients. The company has now changed two franchises: has combined Chronic Care and Pain Management franchises into a single commercial organization focused on the Digestive Health and Pain Management and Recovery product categories that generate its revenue from its Chronic Care franchise and in North America.